AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01386983 — intervention group
Intervention type: DRUG
Intervention: 5ARI + AB
Description: 5ARI: Dutasteride or Finasteride AB: Doxazosin, Tamsulosin, Terazosin, or Alfuzosin
Study NCT02097680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: One Letrozole 2.5 mg capsule every two days during four months
Study NCT02097680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo capsule every two days during four months
Study NCT04465695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b
Description: Subcutaneous injection of interferon β-1b 1mL (0.5mg; 16 million IU) for 3 days
Study NCT04465695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clofazimine
Description: Oral 100mg twice daily on day 1, then 100mg daily for 2 days
Study NCT04465695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine
Description: Oral 100mg twice daily on day 1, then 100mg daily for 2 days
Study NCT03086759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: platelet rich plasm
Description: intra-articular infiltration with platelet rich plasm
Study NCT03086759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Hexacetonide
Description: intra-articular infiltration withTriamcinolone Hexacetonide
Study NCT03086759 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Saline Solution
Description: intra-articular infiltration with Isotonic Saline Solution
Study NCT00224419 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational interviewing for smoking cessation
Description: All participants received a tailored CBT (TCBT) intervention that included: a written self-help guide, info about the importance of reducing nicotine exposure to the fetus, 5 face to face and 1 telephone counseling session. Women in the TCBT + NRT arm were guided through a process of deciding on nicotine gum, lozenge or patch. To minimize fetal exposure, the dose of NRT was customized to the woman's current level of smoking. Women who smoked 5-10 cigarettes a day were given the 14 mg patch or instructed to use one 2 mg lozenge or 2 mg piece of gum to replace each cigarette she usually smoked per day. Those who smoked 11 cigarettes or more per day were given the 21 mg patch or instructed to use no more than one lozenge (2 mg) or piece of gum (2 mg) to replace each cigarette she usually smoked per day, not to exceed 15 lozenges or pieces of gum per day.
Study NCT00224419 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing for smoking cessation
Description: All participants received a tailored CBT (TCBT) intervention that included: a written self-help guide, info about the importance of reducing nicotine exposure to the fetus, 5 face to face and 1 telephone counseling session. Women in the TCBT + NRT arm were guided through a process of deciding on nicotine gum, lozenge or patch. To minimize fetal exposure, the dose of NRT was customized to the woman's current level of smoking. Women who smoked 5-10 cigarettes a day were given the 14 mg patch or instructed to use one 2 mg lozenge or 2 mg piece of gum to replace each cigarette she usually smoked per day. Those who smoked 11 cigarettes or more per day were given the 21 mg patch or instructed to use no more than one lozenge (2 mg) or piece of gum (2 mg) to replace each cigarette she usually smoked per day, not to exceed 15 lozenges or pieces of gum per day.
Study NCT00224419 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behaviors therapy
Description: 6 counseling sessions delivered over the phone or in person
Study NCT00224419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBT + NRT
Description: Includes CBT from arm 1 plus choice of NRT (lozenge, gum, or patch) tailored to smoking amount
Study NCT01056042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intramuscular depot medroxyprogesterone acetate
Description: 150 mg, Intramuscular, every 3 months
Study NCT01056042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ethinyl estradiol 30 micrograms, gestodene 75 micrograms
Description: one tablet orally, everyday
Study NCT01242722 — intervention group
Intervention type: DEVICE
Intervention: CRT-D
Description: Cardiac pacing via a pulse generator and implanted intracardiac leads
Study NCT03176862 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise test
Description: An exercise bicycle test. No stress echocardiogram.
Study NCT03176862 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood test
Description: 20 mls of blood will be taken to measure routine laboratory tests and biomarkers of fibrosis.
Study NCT00902213 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Each patient in this group will have physical therapy performed. The intervention will be tested for its effect on: 1) physical function outcomes (muscle strength, range of motion, endurance, gross motor skills), bone density and bone mineral content (end of therapy only); and 2) HRQL.
Study NCT00902213 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support
Description: Visits with an Advanced Practice Nurse to support sustained motivation.
Study NCT01178944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01178944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT01178944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate
Description: Given IV
Study NCT00640809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg oral capsule twice daily for 2 weeks
Study NCT00640809 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo for 2 weeks
Study NCT00640809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen plus Omeprazole
Description: ibuprofen 800 mg oral tablet three times daily plus omeprazole 20 mg oral capsule once daily for 2 weeks
Study NCT03445377 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Real-time continuous glucose monitoring
Description: Subjects randomised to Real-time continuous glucose monitoring will be given a Dexcom G5 or similar, training on its use, and HbA1c measurements taken at the start and end of the study. They will also be given validated questionnaires to complete.
Study NCT03445377 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Self-monitoring of blood glucose
Description: Subjects randomised to self monitoring of blood glucose will be given a masked CGM which will be applied for one week, during Week 1, 4 and 8. HbA1c measurements will be taken at the start and end of the study. They will also be given validated questionnaires to complete.
Study NCT00553514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human chorionic gonadotropin (r-hCG)
Description: Recombinant human chorionic gonadotropin (r-hCG) will be administered as a single dose of 250 mcg subcutaneously, when follicular response is adequate (that is, less than or equal to \[=\<\] 3 follicles with a mean diameter of greater than or equal to \[>=\] 14 millimeter \[mm\], and one or two of these follicles with a diameter of >= 17 mm).
Study NCT01856413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zutectra
Description: Subcutaneous injections of Zutectra up to 1,000 IU (2 ml) per week.
Study NCT04366453 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: echocardiography
Description: Four measurements in echocardiography performed in addition to standard care
Study NCT04464889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDG1021 dose 1
Description: 3 patients to receive dose1: target dose of 0.3x10\^6 HA-1H TCR transduced T cells/kg BW ±20% in 100 mL
Study NCT04464889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDG1021 dose 2
Description: 3 patients to receive dose 2: target dose of 1x10\^6 HA-1H TCR transduced T cells/kg BW ±20% in 100 mL
Study NCT04464889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDG1021 dose 3
Description: 3 patients to receive dose 3: target dose of 3x10\^6 HA-1H TCR transduced T cells/kg BW +20% in 100 mL
Study NCT04464889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDG1021 optimal dose
Description: 20 patients to receive the selected optimal dose
Study NCT03214393 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Doppler
Description: Doppler will be done to pregnant women with Pre-Eclampsia
Study NCT03214393 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum antibodies
Description: serum antibodies will be measured for pregnant women with Pre-Eclampsia
Study NCT03831165 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 3 mg
Description: melatonin and placebo
Study NCT02661737 — intervention group
Intervention type: DEVICE
Intervention: YVOIRE volume s
Study NCT00617058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: open dosed, randomly assigned flexible dose treatment with 250-2000mg/day divided BID or TID
Study NCT00617058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: healthy lifestyle intervention
Description: additional component to regular psychiatric visits that includes monitoring of lifestyle and eating behaviors.
Study NCT01323088 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Standard care control (no exercise)
Study NCT01323088 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise
Description: Supervised resistance exercise using stack weight equipments.
Study NCT01323088 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Supervised aerobic exercise using treadmills, bikes, and ellipticals
Study NCT03831165 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Description: melatonin and placebo
Study NCT03831165 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Melatonin 3 mg
Description: melatonin and placebo
Study NCT03831165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyclovir
Description: Only acyclovir 200 mg twice a day
Study NCT03831165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Description: Only acyclovir 200 mg twice a day
Study NCT03831165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acyclovir
Description: Only acyclovir 200 mg twice a day
Study NCT04217811 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT00477633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone/ethinyl estradiol
Description: 1 tablet per day
Study NCT02094911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined lifestyle intervention
Description: 10-month intervention period with:~* weekly group-based sports lessons supervised by a physiotherapist~* individual dietary advice by a dietician~* case management by practice nurse~* maintenance programme to guide subjects to maintain lifestyle behaviour change
Study NCT02094911 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care group
Description: Written information on healthy lifestyle was provided at baseline, no individual advice or programme was provided. No additional appointments were scheduled, apart from the visits for follow-up measurements
Study NCT04986384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atoderm SOS spray Aerosol 200ml
Description: A bottle of 200ml topical spray was used on the eczematous skin lesions for itch relief.
Study NCT01777464 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: histamine
Description: administration of histamine solution (16 mg/ml) via aerosol for 5 minutes while lying under a fMRI scan
Study NCT01777464 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: histamine
Description: administration of histamine solution (16 mg/ml) via aerosol for 5 minutes while lying under a fMRI scan
Study NCT03012984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine supplemented morphine analgesia
Description: Patients in this group will receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml each time and a lockout time from 6 to 8 minutes according to patients' condition.
Study NCT03012984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine analgesia
Description: Patients in this group will receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is morphine (0.5 mg/ml) diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml each time and a lockout time from 6 to 8 minutes according to patients' condition.
Study NCT03578666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: The intervention will be applied to both legs to a constant distal to proximal stroking rhythm. Firstly, participants will be lying in a prone position for 22 min: 1 min on the sole of the foot, 1 min on the Achilles tendon, 1 min on the soleus muscle, 3 min on the triceps muscle, 4 min on the hamstring muscles, 30 s tapotement from the sole of the foot to the hamstrings and 30 s superficial effleurage from the sole of the foot to the hamstrings. Then they will assume a supine position for 18 min: 1 min on the sole of the foot, 3 min on the tibialis anterior and peroneus lateralis muscles and 4 min in the quadriceps, adductors and lata muscles, 30 s tapotement from the sole of the foot to the hamstrings and 30 s superficial effleurage from the sole of the foot to the hamstrings.
Study NCT03578666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold water immersion
Description: The cold water immersion group immersed their lower limbs (ensuring that the iliac crests were fully immersed) in an ice bath filled with cooled water for 10 min. The water was maintained at a mean temperature of 10 degrees (±0.5°) by the addition of ice.
Study NCT02662283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Oral take prednisolone (0.5 mg/kg, qd) for 8 weeks
Study NCT01777464 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: sham
Description: sham solution
Study NCT03535272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth subsalicylate
Description: We aim to determine if there is a biologic benefit to an intervention (BSS administration) in the acquisition of travelers diarrhea and the acquisition of antimicrobial resistance genes.
Study NCT03535272 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo manufactured to mimic pepto bismol
Study NCT01777464 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sham
Description: sham solution
Study NCT05533307 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: observational analysis of mediolateral episiotomy with arizona sexuel function scoring after 3 months of normal vaginal birth
Description: ASEX (ARİZONA SEXUEL FONCTİON SCORİNG) TEST
Study NCT02836470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB1148
Description: A total of 700 mL of drug product will be administered orally as a split dose before surgery.
Study NCT02836470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A total of 700 mL of placebo will be administered orally as a split dose before surgery.
Study NCT03900585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval walking
Description: Interval walking administered by an app on the patient's telephone. Interval walking for 150 minutes/week for 10 weeks.
Study NCT01672281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vibrox- vs. resistance training
Description: Comparison between two exercise interventions
Study NCT02894723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-arginine
Description: 30 ml arginoline contains 5 gr l-arginine
Study NCT02894723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: syrup
Description: The same bottle of the experimental group, but without l-arginine
Study NCT01576939 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: We are using thermoluminescent dosimeter (TLD) to measure the mucosal dose adjacent to the dental fillings in a standard, non-filling optimized IMRT (intensity modulated radiotherapy treatment) plan that is normally delivered in the clinic. If the measured mucosal dose exceeds 35 Gy, we will generate a filling optimized IMRT plan to reduce it to \< 35 Gy. The new plan will be deemed acceptable and implemented only if it does not (1) compromise the tumor coverage, (2) increase the dose to either the remaining oral cavity or the spared parotid gland(s).
Study NCT01116999 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: light guided tracheal intubation
Description: Tracheal intubation light guided technique.
Study NCT02487654 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation
Description: Conventional endocardial radiofrequency catheter ablation for pulmonary vein isolation.
Study NCT02487654 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ganglionated plexus ablation
Description: Endocardial radiofrequency catheter ablation of ganglionated plexus in the left atrium
Study NCT00420927 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab 40 mg/0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)
Study NCT03689946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab: In patients without homozygous familial hypercholesterolemia (FH), evolocumab will be self-injected as follows: 140mg every 2 weeks or 420mg once a month subcutaneously.~Patients with homozygous FH will be instructed to administer 420mg subcutaneously once a month by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.
Study NCT03689946 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-NaF PET
Description: 18F-NaF PET: Baseline (pre-treatment) and follow-up dual cardiac and respiratory-gated PET- imaging of the thoracic aorta. Dose of 250 MBq 18F-NaF intravenously.
Study NCT03689946 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CCTA
Description: CCTA: Baseline (pre-treatment) and follow-up CCTA. Bolus injection of 80-100 ml contrast (Omnipaque or Visipaque). Possible beta blocker(metoprolol)administered to achieve a target heart ≤70 beats/min (bpm) and/or 0.4 or 0.8 mg of sublingual nitroglycerin administered, if medical safe.
Study NCT03689946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omnipaque
Description: contrast agent for CCTA
Study NCT03689946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: beta blocker to optimize heart rate during CCTA
Study NCT03689946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Description: premedication for CCTA
Study NCT01010945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: administered orally
Study NCT01010945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: administered intravenously
Study NCT01010945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: administered intravenously
Study NCT02893969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: After 72 hours of full physical rest patients will gradually reintroduce physical activity into their daily routine.
Study NCT02893969 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Rest
Description: Complete physical rest until asymptomatic.
Study NCT01627561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix
Description: 2 doses administered intramuscularly in the deltoid muscle of the left arm at Day 0 and Month 6.
Study NCT01627561 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Priorix
Description: 1 dose administered intramuscularly in the deltoid muscle of the left arm at Day 0.
Study NCT01627561 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix
Description: 1 dose administered intramuscularly in the deltoid muscle of the left arm at Month 6.
Study NCT03422549 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drager VN500 Ventilator
Description: This ventilator is capable of providing both CPAP and NHFOV support.
Study NCT00420927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Methotrexate 2.5 mg tablets administered orally once a week starting at 7.5 mg/week with dose escalation (weekly or every other week) by 2.5 mg intervals to 20 mg/week.